Pathway · Evidence
What supports claims from online peptide specialists
Different questions have different official answers. Whether a medicine is approved, whether it is in short supply, whether a pharmacy may mix it, and whether the FDA has written to a seller are each kept in a different government record. This page tells you which one to open.
Match source to question
Four records, four jobs
A product can show up in a government list, such as the National Drug Code (NDC) directory of product numbers, and still not be approved. Start with the question, then open the record built to answer it.
| Question | Best record | What it does not prove |
|---|---|---|
| Is the product approved? | FDA approval record and current label. | An NDC entry alone does not show approval. |
| Is a drug in national shortage? | FDA Drug Shortages record. | A local backorder is not a national shortage listing. |
| May a bulk ingredient be compounded? | The FDA’s list of allowed ingredients, and its lists of ingredients still under review. | If someone asked the FDA to allow an ingredient and then took the request back, that is not approval. |
| Has the FDA raised concerns? | FDA company letters and agency alerts. | A warning letter is an allegation at one point in time, not a court ruling. |
Where things stand
What the records showed in September
As of September 2026, semaglutide injection and tirzepatide were not on the FDA Drug Shortages list. While they were in short supply, pharmacies were allowed to make their own copies; now that the shortage is over, that permission has ended for those products.
- As of September 2026, no generic version of Ozempic, Wegovy, Mounjaro, or Zepbound could be sold in the United States.
- As of September 2026, the FDA said pharmacies may not use two newer weight-loss ingredients, retatrutide and cagrilintide, in compounding at all. An offer of either one is not a lawful made-to-order medicine.
- As of September 2026, the FDA had no file asking to approve any of these peptides often sold online: BPC-157, ipamorelin, epitalon, MOTS-c, thymosin alpha-1, or retatrutide. None of them is an approved medicine in the United States, so an offer of one is not a care route.
Approval, shortage, and compounding sources
A word that gets misread
“Withdrawn” is not “cleared”
People and groups can ask the FDA to add an ingredient to the list pharmacies may use; that request is called a nomination. On the FDA page current as of April 22, 2026, several familiar peptides were listed as nominations that the people who made them had withdrawn, meaning taken back. The FDA kept its safety concerns beside those names.
- Taking the request back does not put an ingredient on the official allowed list.
- It also does not place the ingredient on the FDA’s temporary list of ingredients pharmacies may keep using while the FDA decides.
- No minutes, transcript, or official vote record for the FDA’s July 2026 meeting of outside advisers on seven peptides had been published by the FDA as of September 2026. Until it does, no one can point to an official record of what the advisers recommended.
The FDA records behind this wording
Keep a private question list
Your note stays in this browser on this device. Nothing is sent to this site.